New FDA Approved Drug Combo Offers Hope For Patients
Dec 18, 2025 · Understanding HER+ Breast Cancer A new FDA-approved treatment for HER2-positive metastatic breast cancer—trastuzumab deruxtecan (Enhertu) in combination with …
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic …
Dec 15, 2025 · The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.
HER2-Targeted Therapies for Metastatic Breast Cancer
Mar 3, 2025 · Trastuzumab deruxtecan is FDA-approved for the treatment of HER2-positive metastatic breast cancers that have progressed on at least one past HER2-targeted therapy …
T-DXd Wins First-Line Indication for HER2+ Breast Cancer
Dec 16, 2025 · FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or metastatic HER2-positive breast cancer.
Treating HER2+ Metastatic Breast Cancer - herceptin
Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.
FDA Approves T-DXd With Pertuzumab for First-Line Treatment …
Dec 15, 2025 · The FDA approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu; Daiichi Sankyo, Inc., AstraZeneca) in combination with pertuzumab (Perjeta; Genentech) for the first …
T-DXd Plus Pertuzumab Outperforms Standard of Care for First …
Jun 2, 2025 · HER2-positive breast cancer accounts for approximately 15 to 20 percent of metastatic breast cancers. HER2-targeted therapies have improved outcomes dramatically for …
T-DXd Breakthrough Designation Signals New Era for HER2 …
Jul 21, 2025 · The FDA has granted breakthrough therapy designation to the combination of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) and pertuzumab (Perjeta) for the first-line …
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki With …
On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) in combination with pertuzumab for the first-line treatment of …
Trastuzumab: Targeted therapy for breast cancer | LBBC
Trastuzumab (brand name: Herceptin) is a targeted therapy known as a monoclonal antibody, a modified version of an immune system protein, that can attach to proteins on HER2-positive …